Welcome to our dedicated page for Harpoon Therapeutics news (Ticker: HARP), a resource for investors and traders seeking the latest updates and insights on Harpoon Therapeutics stock.
Harpoon Therapeutics, Inc. (NASDAQ: HARP) is a clinical-stage immunotherapy company founded in 2015. Specializing in developing T cell engagers, Harpoon harnesses the body’s immune system to combat cancer and other serious diseases. Co-founded by Patrick Bauerle and Luke Evnin, the company leverages groundbreaking T cell recruiting antibodies to develop next-generation therapies. Harpoon's innovative platforms include the Tri-specific T cell Activating Construct (TriTAC®), ProTriTAC™, and TriTAC-XR. The TriTAC® platform aims to direct a patient's own immune cells to target and destroy tumor cells, primarily focusing on solid tumors and hematologic malignancies.
One of Harpoon's leading projects is HPN328, targeting delta-like ligand 3 (DLL3). Currently in a Phase 1/2 clinical trial, HPN328 shows promise in treating small cell lung cancer (SCLC) and other neuroendocrine tumors. Interim results indicate a 35% confirmed response rate in all tumor types studied, with higher efficacy observed in non-SCLC neuroendocrine tumors.
Harpoon's innovative approach extends to their proprietary ProTriTAC™ platform, which remains inactive until reaching the tumor, ensuring higher precision and reduced side effects. Additionally, the TriTAC-XR platform is designed to mitigate cytokine release syndrome, a common challenge in T cell therapies.
Financially, Harpoon has secured robust funding through recent PIPE financings, ensuring a solid runway into 2026. Strategic partnerships with leading oncology research centers and a strong focus on regulatory milestones underscore Harpoon's commitment to advancing cancer treatment. For more information, visit www.harpoontx.com.
- HPN328 received Orphan Drug Designation from the FDA in March 2022.
- The company is actively presenting data at major oncology conferences such as ESMO and ASCO-GU.
- Harpoon plans to meet with regulators in early 2024 to discuss further development plans for HPN328.
On October 26, 2021, Harpoon Therapeutics announced the appointment of Julie Eastland as its new President and CEO, effective November 8, 2021. She succeeds Jerry McMahon, who has resigned but will serve as an advisor. Eastland, a current board member with over 20 years in biotechnology, aims to advance the company's clinical cancer treatments. Scott Myers has been named Chair of the Board, succeeding Ron Hunt. This leadership change is seen as a strategic move to enhance Harpoon's capabilities in developing its T cell engager technology platforms.
Harpoon Therapeutics (NASDAQ: HARP) announced that an abstract featuring preclinical data from its TriTAC-XR T cell engager platform has been accepted for poster presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), scheduled for November 10-14, 2021. The abstract, titled TriTAC-XR is an extended-release T cell engager platform, aims to minimize cytokine release syndrome. The full abstract will be released on November 9, 2021, highlighting Harpoon's commitment to advancing immunotherapy for cancer treatment.
Harpoon Therapeutics (NASDAQ: HARP) announced that its CEO, Gerald McMahon, will participate in three virtual investor conferences in September 2021. The events include a panel discussion at Citi’s 16th Annual BioPharma Conference on September 9, a fireside chat at Baird’s 2021 Global Healthcare Conference on September 15, and another fireside chat at Cantor’s 2021 Virtual Global Healthcare Conference on September 28. Live webcasts will be accessible on the company’s website.
Harpoon Therapeutics reported its Q2 2021 financial results and clinical updates on its TriTAC platform. The interim clinical data for HPN424 in prostate cancer revealed it was well-tolerated and active, with some patients showing significant treatment responses. The company ended Q2 with $175.2M in cash, up from $150M at year-end 2020. Revenue surged to $5.8M, driven by collaborations with AbbVie. However, net loss increased to $16.8M in Q2 2021 from $12.7M in Q2 2020. Anticipated milestones for HPN424 and other programs will be reported by year-end 2021.
Harpoon Therapeutics, a clinical-stage immunotherapy company, announced that its CEO Gerald McMahon will participate in two upcoming virtual investor conferences. The first is a panel discussion titled “Heavenly (anti)Bodies” at the 2021 Wedbush PacGrow Healthcare Virtual Conference on August 10, 2021, at 1:10 p.m. ET. The second is a presentation at the Canaccord Genuity 41st Annual Growth Conference on August 11, 2021, at 10:30 a.m. ET, with a live webcast available on the company’s website.
Harpoon is developing innovative T cell engagers to treat cancer and other diseases.
Harpoon Therapeutics (NASDAQ: HARP) announced positive interim results from its TriTAC clinical programs (HPN424, HPN536, HPN328) at ASCO 2021. The trials demonstrated tumor size reductions or stable disease, extending treatment duration in heavily pretreated patients. The company manages cytokine release syndrome effectively, with a low incidence of severe cases. HARP will host a webcast at 4 p.m. ET to discuss findings and pipeline updates.
Harpoon Therapeutics announced interim results from its ongoing Phase 1/2a trial of HPN424 for metastatic castration-resistant prostate cancer. As of April 23, 2021, 89 patients were enrolled across 13 cohorts. The data indicates that HPN424 is generally well tolerated, with manageable cytokine-related adverse events. Notably, there were reductions in serum PSA levels, including confirmed partial responses in patients. The company plans to host a conference call to discuss these findings and future pipeline developments today at 4 p.m. ET.
Harpoon Therapeutics will present updated interim Phase 1 data for its prostate cancer treatment HPN424 at the upcoming ASCO Annual Meeting on June 4, 2021. The poster will detail results from a Phase 1/2a clinical trial focusing on metastatic castration-resistant prostate cancer (mCRPC), employing the proprietary TriTAC platform to engage the immune system. Management will also host a webcast at 4 p.m. ET on the same day to discuss the data and pipeline updates.
Harpoon Therapeutics reported promising advancements in their TriTAC and ProTriTAC platforms during the AACR Annual Meeting. The company experienced a surge in revenue, reaching $9.0 million in Q1 2021, up from $3.3 million in Q1 2020, primarily due to collaboration with AbbVie. However, Harpoon faced a net loss of $61.7 million, significantly higher than the previous year's $12.6 million. Notably, the company completed a $107.6 million financing round. Additionally, a settlement agreement resulted in a $50 million litigation expense, reflecting ongoing operational challenges.
Harpoon Therapeutics (NASDAQ: HARP) announced that CEO Jerry McMahon, Ph.D., will participate in a fireside chat at the 7th Annual Truist Securities Life Sciences Summit on May 5, 2021, at 10:30 a.m. ET. A live audio webcast will be available on Harpoon's website, with an archived replay following the event.
Harpoon is focused on developing T cell engagers for cancer treatment, utilizing its TriTAC platform. Key pipeline candidates include HPN424, HPN536, HPN217, and HPN328, targeting various cancers. For more details on Harpoon's innovation, visit their website.
FAQ
What is the market cap of Harpoon Therapeutics (HARP)?
What is Harpoon Therapeutics' primary focus?
What is the TriTAC® platform?
What are the recent clinical trial updates for HPN328?
What does the ProTriTAC™ platform do?
What is the significance of TriTAC-XR?
What financial steps has Harpoon taken recently?
What is HPN328 targeting?
When did HPN328 receive Orphan Drug Designation?
Where can I find more information about Harpoon Therapeutics?
What are Harpoon’s plans for HPN328 in 2024?
